In MM, anemia results from bone marrow infiltration, relative erythropoietin (EPO) deficiency, chemotherapy-induced myelosuppression (32), and nutritional deficiencies (iron, B12, and folate) (33), which increase Hb variability and reduce its reliability as a cardiac risk marker. The gene discussed is GSTM1; the disease is Miyoshi myopathy.